Search
Search Results
##search.searchResults.foundPlural##
-
Evaluating the use of meropenem in hematologic patients with febrile neutropenia A retrospective observational single-cohort study
1395PDF: 571HTML: 165 -
Ceftolozane-Tazobatam for febrile neutropenia treatment in hematologic malignancy patients colonized by multi-resistant Enterobacteriaceae: preliminary results from a prospective cohort study Ceftolozane-Tazobatam for febrile neutropenia
8044PDF: 794HTML: 274 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2898PDF: 911HTML: 15042Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 395 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
2084PDF: 1136HTML: 270 -
THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association
1235PDF: 1315HTML: 150 -
TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL Sirapat Rungwittayatiwat1, Paisarn Boonsakan2, Pichika Chantrathammachart1, Teeraya Puavilai1, Sulada Pukiat1, Sithakom Phusanti1,3, Kochawan Boonyawat1, Pathawut Wacharapornin1, Pantep Angchaisuksiri1, Artit Ungkanont1,3, Suporn Chuncharunee1 Pimjai Niparuck1
1351PDF: 638HTML: 287 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1786PDF: 1160HTML: 511 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1643PDF: 1352HTML: 542 -
-
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
3107PDF: 1196HTML: 137 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4163PDF: 1139HTML: 3919Untitled: 205Cneo. Fig.1: 147Untitled: 138Untitled: 173Untitled: 175 -
ASSOCIATION OF BASELINE PLATELET COUNT WITH COMPLETE REMISSION, SEVERE BLEEDING, AND 24-MONTH OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY
175PDF: 137Suppl. Files: 28Html: 31Html Suppl. Files: 23 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1623PDF: 879HTML: 381 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2415PDF: 960HTML: 2030Fig 1 Rossi: 250 -
CORD BLOOD PLATELET LYSATE: IN VITRO EVALUATION TO SUPPORT THE USE IN REGENERATIVE MEDICINE. Cord and adult blood platelet lysates
2281PDF: 1249HTML: 292 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4635PDF: 1845HTML: 1133 -
THE CHALLENGE OF AML IN OLDER PATIENTS
2500PDF: 1078HTML: 2241







